Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents
Authors
Keywords
-
Journal
Expert Opinion on Drug Metabolism & Toxicology
Volume 11, Issue 9, Pages 1419-1433
Publisher
Informa Healthcare
Online
2015-07-15
DOI
10.1517/17425255.2015.1057496
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The evaluation of gender on the pharmacokinetics (PK) of pegylated liposomal anticancer agents.
- (2017) N. M. La-Beck et al. JOURNAL OF CLINICAL ONCOLOGY
- The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents
- (2015) Jennifer S Petschauer et al. Nanomedicine
- Synergy of Nab-paclitaxel and Bevacizumab in Eradicating Large Orthotopic Breast Tumors and Preexisting Metastases
- (2015) Lisa D. Volk et al. NEOPLASIA
- Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old
- (2014) Milena Gusella et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models
- (2014) G. Song et al. CLINICAL CANCER RESEARCH
- Preparation, Characterization, and Pharmacodynamics of Thermosensitive Liposomes Containing Docetaxel
- (2014) Hui Zhang et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Nanocarriers for delivery of platinum anticancer drugs
- (2013) Hardeep S. Oberoi et al. ADVANCED DRUG DELIVERY REVIEWS
- Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
- (2013) Nicolas Bertrand et al. ADVANCED DRUG DELIVERY REVIEWS
- Future of the Particle Replication in Nonwetting Templates (PRINT) Technology
- (2013) Jing Xu et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy
- (2013) Kevin S. Chu et al. BIOMATERIALS
- Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology
- (2013) U. Prabhakar et al. CANCER RESEARCH
- Changes in macrophage phenotype as the immune response evolves
- (2013) Julia Lichtnekert et al. CURRENT OPINION IN PHARMACOLOGY
- Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: Final results of the DOGMES multicentre GINECO trial
- (2013) C. Falandry et al. EUROPEAN JOURNAL OF CANCER
- Gene Therapy Delivery Systems for Enhancing Viral and Nonviral Vectors for Cardiac Diseases: Current Concepts and Future Applications
- (2013) Michael G. Katz et al. HUMAN GENE THERAPY
- Mind the gap: A survey of how cancer drug carriers are susceptible to the gap between research and practice
- (2013) Darren Lars Stirland et al. JOURNAL OF CONTROLLED RELEASE
- Emerging Research and Clinical Development Trends of Liposome and Lipid Nanoparticle Drug Delivery Systems
- (2013) John C. Kraft et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Anthracycline nano-delivery systems to overcome multiple drug resistance: A comprehensive review
- (2013) Ping Ma et al. Nano Today
- Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles
- (2013) Randall Toy et al. Nanomedicine
- Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents
- (2013) Ryan F. Schell et al. Nanomedicine-Nanotechnology Biology and Medicine
- Strategies for advancing cancer nanomedicine
- (2013) Vikash P. Chauhan et al. NATURE MATERIALS
- Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle
- (2013) S. Eliasof et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combining two strategies to improve perfusion and drug delivery in solid tumors
- (2013) T. Stylianopoulos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Challenges in Development of Nanoparticle-Based Therapeutics
- (2012) Neil Desai AAPS Journal
- Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
- (2012) Susana Patricia Egusquiaguirre et al. Clinical & Translational Oncology
- Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance
- (2012) W. C. Zamboni et al. CLINICAL CANCER RESEARCH
- Interpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier-Mediated Anticancer Agents
- (2012) W P Caron et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Drug-Loaded Nanocarriers: Passive Targeting and Crossing of Biological Barriers
- (2012) J. M. Rabanel et al. CURRENT MEDICINAL CHEMISTRY
- Brain delivery of camptothecin by means of solid lipid nanoparticles: Formulation design, in vitro and in vivo studies
- (2012) Susana Martins et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft
- (2012) Kevin S. Chu et al. Nanomedicine-Nanotechnology Biology and Medicine
- Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)
- (2011) Jürgen Eckes et al. BMC CANCER
- Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients
- (2011) Ninh M. La-Beck et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Abstract 3700: Effect of gender on pharmacokinetic disposition of pegylated liposomal CKD-602 (S-CKD602) and optisomal topotecan (TLI) in rats
- (2011) Gina Song et al. CANCER RESEARCH
- Liposomal drug formulations in cancer therapy: 15 years along the road
- (2011) Marije Slingerland et al. DRUG DISCOVERY TODAY
- Population Pharmacokinetics of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies
- (2011) Huali Wu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer
- (2011) Maurie Markman Cancer Management and Research
- The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
- (2010) Jun Fang et al. ADVANCED DRUG DELIVERY REVIEWS
- Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
- (2010) C. Rochlitz et al. ANNALS OF ONCOLOGY
- Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial
- (2010) G. P. Stathopoulos et al. ANNALS OF ONCOLOGY
- Translational considerations for cancer nanomedicine
- (2010) Stephan T. Stern et al. JOURNAL OF CONTROLLED RELEASE
- Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors
- (2010) William C. Zamboni et al. JOURNAL OF LIPOSOME RESEARCH
- Nanopharmacology of liposomes developed for cancer therapy
- (2010) Madaswamy S Muthu et al. Nanomedicine
- XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer
- (2009) Alexander V. Yurkovetskiy et al. ADVANCED DRUG DELIVERY REVIEWS
- Pharmacokinetic Study of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies
- (2009) W C Zamboni et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Minireview: Nanoparticles and the Immune System
- (2009) Banu S. Zolnik et al. ENDOCRINOLOGY
- Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin
- (2009) Teni Boulikas EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Peptide- and Aptamer-Functionalized Nanovectors for Targeted Delivery of Therapeutics
- (2009) Todd O. Pangburn et al. JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME
- Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer
- (2009) N. Mylonakis et al. LUNG CANCER
- The aging of the immune system
- (2009) Daniela Weiskopf et al. TRANSPLANT INTERNATIONAL
- A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): A gynecologic oncology group study
- (2008) Paul Sabbatini et al. GYNECOLOGIC ONCOLOGY
- Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development
- (2008) Daryl C. Drummond et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Pharmacokinetics and Biodistribution of Nanoparticles
- (2008) Shyh-Dar Li et al. MOLECULAR PHARMACEUTICS
- Preclinical Studies To Understand Nanoparticle Interaction with the Immune System and Its Potential Effects on Nanoparticle Biodistribution
- (2008) Marina A. Dobrovolskaia et al. MOLECULAR PHARMACEUTICS
- Physical approaches to biomaterial design
- (2008) Samir Mitragotri et al. NATURE MATERIALS
- Concept and Clinical Evaluation of Carrier-Mediated Anticancer Agents
- (2008) W. C. Zamboni ONCOLOGIST
- Cancer-Cell-Phenotype-Dependent Differential Intracellular Trafficking of Unconjugated Quantum Dots
- (2008) Sutapa Barua et al. Small
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now